BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001;7:513-517. [PMID: 11443579 DOI: 10.1053/jlts.2001.23911] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005;11:716-32. [DOI: 10.1002/lt.20492] [Cited by in Crossref: 127] [Cited by in F6Publishing: 104] [Article Influence: 7.5] [Reference Citation Analysis]
2 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transplant Int 2004;17:746-58. [DOI: 10.1111/j.1432-2277.2004.tb00507.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
3 Seem DL, Lee I, Umscheid CA, Kuehnert MJ; United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013;128:247-343. [PMID: 23814319 DOI: 10.1177/003335491312800403] [Cited by in Crossref: 158] [Cited by in F6Publishing: 127] [Article Influence: 17.6] [Reference Citation Analysis]
4 Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010;4:707-15. [PMID: 21286341 DOI: 10.1007/s12072-010-9188-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
5 Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-41. [DOI: 10.1111/j.1365-2036.2006.02855.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
6 Fondevila C, Jiménez-Galanes S, García-Valdecasas JC. [How can the number of liver transplantations be increased?]. Gastroenterol Hepatol 2009;32:519-30. [PMID: 19608299 DOI: 10.1016/j.gastrohep.2009.01.184] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C, Rando-Muñoz FJ. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol 2015; 21(42): 12083-12090 [PMID: 26576093 DOI: 10.3748/wjg.v21.i42.12083] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
8 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006;19:38-43. [PMID: 16359375 DOI: 10.1111/j.1432-2277.2005.00225.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
10 Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85. [DOI: 10.1002/lt.20258] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
11 Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl. 2003;9:837-842. [PMID: 12884197 DOI: 10.1053/jlts.2003.50157] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
12 Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl. 2003;9:451-462. [PMID: 12740786 DOI: 10.1053/jlts.2003.50094] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
13 Hui C, Cheung WW, Chan S, Lo C, Lau GK. Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation. Current Opinion in Organ Transplantation 2006;11:594-8. [DOI: 10.1097/mot.0b013e32801040bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant. 2007;7:195-200. [PMID: 17227568 DOI: 10.1111/j.1600-6143.2006.01618.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
15 Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272-279. [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009] [Cited by in Crossref: 185] [Cited by in F6Publishing: 146] [Article Influence: 15.4] [Reference Citation Analysis]
16 Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009;15:223-232. [PMID: 19177436 DOI: 10.1002/lt.21675] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
17 Mutimer D. Positive suggestions about the anti-HBc positive donor. Gut 2002;50:7-8. [PMID: 11772957 DOI: 10.1136/gut.50.1.7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Fontana R. Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transplantation 2003;9:833-6. [DOI: 10.1053/jlts.2003.50141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
19 López-Navidad A, Caballero F. Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool. Clin Transplant. 2003;17:308-324. [PMID: 12868987 DOI: 10.1034/j.1399-0012.2003.00119.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 74] [Article Influence: 5.4] [Reference Citation Analysis]
20 Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 2001;7:S60-S73. [PMID: 11689778 DOI: 10.1053/jlts.2001.29094] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
21 Lee YJ, Oh SH, Kim KM, Song SM, Namgoong JM, Kim DY, Lee SG. De novo hepatitis B virus infection after pediatric liver transplantations with hepatitis B core antibody-positive donors: a single-center 20-yr experience. Pediatr Transplant. 2015;19:267-272. [PMID: 25648049 DOI: 10.1111/petr.12432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
22 Lankarani KB, Talebzadeh M, Eshraghian A, Malek-Hosseini SA. Granulocyte colony stimulating factor adjuvant role on the immunological response to hepatitis B vaccine in patients with cirrhosis: a double blind randomized placebo controlled trial. Hepat Mon. 2014;14:e15447. [PMID: 24910704 DOI: 10.5812/hepatmon.15447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Castells L. [Viral hepatitides infections in transplant recipients]. Enferm Infecc Microbiol Clin 2006;24:118-28. [PMID: 16545319 DOI: 10.1157/13085018] [Reference Citation Analysis]
24 Prada Lobato J, Garrido López S, Catalá Pindado MA, García Pajares F. [The prophylaxis against post-liver-transplant hepatitis B re-infection]. Farm Hosp 2007;31:30-7. [PMID: 17439311 DOI: 10.1016/s1130-6343(07)75708-2] [Reference Citation Analysis]
25 Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Ng IO, Wong J. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl. 2003;9:827-832. [PMID: 12884195 DOI: 10.1053/jlts.2003.50115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
26 Anwar N, Sherman KE. Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical? J Viral Hepat. 2018;25:1110-1115. [PMID: 29968277 DOI: 10.1111/jvh.12962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 2005;17:746-58. [PMID: 15688165 DOI: 10.1007/s00147-004-0797-1] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
28 Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev Anti Infect Ther 2011;9:685-700. [PMID: 21692673 DOI: 10.1586/eri.11.43] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
29 Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010;16:885-894. [PMID: 20583085 DOI: 10.1002/lt.22084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
30 de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation. 2003;75:S49-S53. [PMID: 12589141 DOI: 10.1097/01.tp.0000047006.96782.64] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
31 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
32 Singh G, Selby R, Genyk Y, Mateo R, Sher L, Jabbour N. Using hepatitis-positive donors for solid organ transplantation: . Current Opinion in Organ Transplantation 2003;8:341-7. [DOI: 10.1097/00075200-200312000-00014] [Reference Citation Analysis]
33 Kerkar N. Hepatitis B in children: complexities in management. Pediatr Transplant 2005;9:685-91. [PMID: 16176431 DOI: 10.1111/j.1399-3046.2005.00393.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
34 Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-S165. [PMID: 19399803 DOI: 10.1002/hep.22945] [Cited by in Crossref: 375] [Cited by in F6Publishing: 327] [Article Influence: 28.8] [Reference Citation Analysis]
35 Flores PA, Vierling JM. Modifications of immunosuppression in hepatitis B virus infection: . Current Opinion in Organ Transplantation 2001;6:331-7. [DOI: 10.1097/00075200-200112000-00011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
36 Loss GE, Mason AL, Nair S, Blazek J, Farr G, Guo L, Cohen AJ, Eason JD. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl. 2003;9:1258-1264. [PMID: 14625825 DOI: 10.1016/j.lts.2003.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
37 Villamil FG. Hepatitis B: progress in the last 15 years. Liver Transpl. 2002;8:S59-S66. [PMID: 12362301 DOI: 10.1053/jlts.2002.35782] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
38 Ni Y, Chang M. The ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation: still many stones left unturned. Pediatric Transplantation 2006;10:405-7. [DOI: 10.1111/j.1399-3046.2006.00494.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
39 Castells L, Vargas V, Rodr[iacute]guez F, Allende H, Buti M, S[aacute]nchez-avila JF, Jard[iacute] R, Margarit C, Pumarola T, Esteban R, Guardia J. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transplantation;8:892-900. [DOI: 10.1053/jlts.2002.35555] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
40 Onoe T, Tahara H, Tanaka Y, Ohdan H. Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol 2016; 22(1): 165-175 [PMID: 26755868 DOI: 10.3748/wjg.v22.i1.165] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
41 Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol 2007;41:66-74. [PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Andreone P, Lorenzini S, Gramenzi A, Biselli M, Cursaro C, Bernardi M. Prophylaxis and treatment of hepatis B virus infection after liver transplantation. Transplant Proc 2003;35:1022-4. [PMID: 12947844 DOI: 10.1016/s0041-1345(03)00254-9] [Reference Citation Analysis]
43 Muñoz S. Use of hepatitis B core antibody–positive donors for liver transplantation. Liver Transplantation 2002;8:S82-7. [DOI: 10.1053/jlts.2002.35783] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
44 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 2009;9:S116-30. [DOI: 10.1111/j.1600-6143.2009.02902.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
45 Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883. [PMID: 12360427 DOI: 10.1053/jlts.2002.34923] [Cited by in Crossref: 291] [Cited by in F6Publishing: 279] [Article Influence: 15.3] [Reference Citation Analysis]
46 Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. The Journal of Heart and Lung Transplantation 2005;24:34-7. [DOI: 10.1016/j.healun.2003.09.036] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
47 Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J. Anti-HBc–positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. Clinics and Research in Hepatology and Gastroenterology 2014;38:475-80. [DOI: 10.1016/j.clinre.2014.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15:1343-1350. [PMID: 19790164 DOI: 10.1002/lt.21788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
49 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
50 Avelino-Silva VI, D’Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, De Brito Neves A, Abdala E. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant. 2010;24:735-746. [PMID: 20438579 DOI: 10.1111/j.1399-0012.2010.01254.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
51 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
52 Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010;16:300-307. [PMID: 20209589 DOI: 10.1002/lt.21998] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
53 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
54 Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003;75:1179-1186. [PMID: 12717200 DOI: 10.1097/01.tp.0000065283.98275.fe] [Cited by in Crossref: 69] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
55 Gallegos-orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. Journal of Hepatology 2004;41:512-21. [DOI: 10.1016/j.jhep.2004.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
56 Yu AS, Keeffe EB. Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clinics in Liver Disease 2003;7:551-72. [DOI: 10.1016/s1089-3261(03)00044-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Jothimani D, Venugopal R, Vij M, Rela M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol. 2020;46-47:101689. [PMID: 33158469 DOI: 10.1016/j.bpg.2020.101689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006;81:1851-2. [PMID: 16631684 DOI: 10.1016/j.athoracsur.2005.12.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
59 Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int 2011;5:635-43. [PMID: 21484133 DOI: 10.1007/s12072-010-9250-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
60 Yen RD, Bonatti H, Mendez J, Aranda-michel J, Satyanarayana R, Dickson RC. Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor: De Novo HB Infection from an HB Core Antibody Donor . American Journal of Transplantation 2006;6:1077-83. [DOI: 10.1111/j.1600-6143.2006.01313.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
61 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
62 Akoad M, Wagener M, Francis F, Ahmed J, Ulizio D, Cacciarelli T. Outcome of Imported Liver Allografts and Impact on Patient Access to Liver Transplantation. Transplantation Proceedings 2006;38:3564-6. [DOI: 10.1016/j.transproceed.2006.10.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
64 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
65 Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int. 2011;24:570-581. [PMID: 21401727 DOI: 10.1111/j.1432-2277.2011.01236.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
66 Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25:1169-1174. [PMID: 16343068 DOI: 10.1111/j.1478-3231.2005.01165.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
67 Montalbano M, Neff GW. Management of recurrent viral hepatitis B and C after liver transplantation. Curr Gastroenterol Rep 2006;8:60-6. [PMID: 16510036 DOI: 10.1007/s11894-006-0065-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Kim H, Choi J. Prophylaxis for Hepatitis B Core Antibody-Positive Donors after Liver Transplantation. J Korean Soc Transplant 2010;24:73. [DOI: 10.4285/jkstn.2010.24.2.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Taylor R, Pietroski R, Hagan M, Eisenbrey A, Fontana R. Seropositive Abdominal and Thoracic Donor Organs Are Largely Underutilized. Transplantation Proceedings 2010;42:4479-87. [DOI: 10.1016/j.transproceed.2010.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Verna EC. Hepatitis viruses and liver transplantation: evolving trends in antiviral management. Clin Liver Dis. 2014;18:575-601. [PMID: 25017077 DOI: 10.1016/j.cld.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
71 Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant. 2006;20:369-373. [PMID: 16824156 DOI: 10.1111/j.1399-0012.2006.00495.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
72 Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-1508 [PMID: 26085909 DOI: 10.4254/wjh.v7.i11.1494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Vizzini G, Gruttadauria S, Volpes R, D’Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant. 2011;25:E77-E81. [PMID: 21039887 DOI: 10.1111/j.1399-0012.2010.01329.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
74 Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant. 2011;25:E243-E249. [PMID: 21323735 DOI: 10.1111/j.1399-0012.2011.01409.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]